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Purpose: To determine the effect of formoterol (formoterol fumarate dihydrate) on the 
aerobic and anaerobic capacities of highly trained athletes. 
 
Methods: 10 male athletes (age = 26.2 +/- 0.9, O2max = 65.6 +/- 2.4 mL[middle 
dot]kg-1[middle dot]min-1) with minimal bronchial reactivity to aerosols (i.e., 
negative methacholine challenge test) completed three identical exercise sessions 
differing only by the medication administered. Formoterol (F) a long-acting [beta]2-
agonist, presently not approved for international competition by the I.O.C. Medical 
committee, was compared with salbutamol (S), an accepted bronchodilator, and a 
placebo (P). Formoterol (12 [mu]g), salbutamol (400 [mu]g), or placebo was 
administered by a Turbuhaler, 10 min before exercise testing in a double-blind, 
randomized, three-way crossover design. Testing sessions included a Wingate 
anaerobic test followed 15 min later by an incremental cycle ergometer test to 
exhaustion. 
 
Results: There were no significant differences between the groups in O2max (F = 
66.5 +/- 2.7; S = 67.8 +/- 2.5; P = 67.5 +/- 2.1 mL[middle dot]kg-1[middle dot]min-1) 
or Wingate peak power (F = 885 +/- 40; S = 877 +/- 40; P = 885 +/- 44 W) values. 
During the maximal aerobic test, no differences were observed in maximum minute 
ventilation, respiratory exchange ratio, heart rate, or work between the three 
experimental conditions. Also, there were no differences in the Wingate anaerobic test 
variables, total work, or fatigue index. 
 
Conclusion: Formoterol, administered in one aerosolized therapeutic dose, does not 
have an ergogenic effect in elite athletes without asthma. 
 
(C) 2002 Lippincott Williams & Wilkins, Inc. 
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